Our ability to obtain an appointment time did not differ across urology vs. radiation oncology practices (89.4% vs. 87.5%) despite the different clinical context (initial evaluation for an elevated PSA vs. consultation for biopsy proven prostate cancer). The gene discussed is KLK3; the disease is prostate carcinoma.